gsk glp 1 agonist Triple Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Current Insights, Advantages and Challenges

Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction [30] [31], offering potential advantages regarding administration route and patient convenience

For example, triple-target agonists like retatrutide are leading multi-target GLP-1 drugs

J Cell Mol Med

Exenatide and lixisenatide are exendin 4-based agents, while albiglutide, dulaglutide, liraglutide, and semaglutide are GLP-1-based agents

They regulate blood sugar and appetite by mimicking the action of the naturally occurring gut hormone GLP-1, a modulator of insulin secretion, glucagon, stomach emptying, and satiety signalling